Recognition for SinterCast at North American International Auto Show
13.1.2016 08:01 | NASDAQ OMX
Ram 1500 diesel engine wins third consecutive Wards 10 Best Engines award
Nissan Titan XD earns finalist position in the Truck of the Year awards
SinterCast-CGI petrol engine in six Ford and Lincoln vehicles
[Detroit, 13 January 2016] - An important part of SinterCast's annual calendar, the 2016 North American International Auto Show (NAIAS) provided a positive start to the year, with new recognition for SinterCast's Compacted Graphite Iron (CGI) engine technology, including the following highlights:
Ram 1500 EcoDiesel: The 3.0 litre V6 diesel engine, with a SinterCast-CGI cylinder block and bedplate designed and produced by VM Motori, won a third consecutive Wards 10 Best Engines award. The CGI diesel was the only engine to receive a third consecutive award; one of only two repeat winners; and, was the only diesel among the ten winning engines. The judging panel commented that the Ram EcoDiesel set the "gold standard for refinement and fuel efficiency in the world of light duty trucks". The Ram 1500 EcoDiesel also retained the best-in-class fuel economy rating at NAIAS in the full size light duty pick-up sector.
Nissan Titan: The all-new Nissan Titan XD pick-up truck, with a 5.0 litre V8 diesel engine designed and built by Cummins, based on a SinterCast-CGI cylinder block, was honoured as one of the three finalists in the North American Truck of the Year award. In a competition that included 21 trucks and sport utility vehicles, the Titan was the only pick-up to earn a spot as a finalist, together with the Volvo XC90 and the Honda Pilot. The recognition as a finalist provides momentum to the Titan in parallel with the start of sales. The Truck of the Year award is highly respected throughout the industry. Now in its 23rd year, it is the only award given by an independent group of automotive journalists rather than by a single media outlet.
Lincoln Continental: Lincoln unveiled the 2017 Continental on 12 January, with a 3.0 litre V6 CGI EcoBoost petrol engine. The engine is a uniquely designed derivative of the SinterCast-CGI 2.7 litre petrol engine and is available only for Lincoln brand vehicles. The twin turbo 3.0 litre engine is projected to provide 400 horsepower and to be the most performant engine in the Lincoln's history. The SinterCast-CGI 2.7 and 3.0 litre petrol engines are also available in the Lincoln MKX luxury crossover and the MKZ luxury sedan.
Ford F-Series pick-ups: Ford retained the best-selling truck title for the 39th consecutive year, with the F-150 being the best-selling vehicle in North America in 2015. Ford noted that globally, throughout 2015, an F-Series pick-up was sold every 18 seconds. Approximately 25% of Ford F-150 pick-ups are sold with the SinterCast-CGI 2.7 litre V6 petrol engine while more than 80% of F-250 through F-750 Super Duty trucks are sold with the SinterCast-CGI 6.7 litre V8 diesel engine. The 2.7 litre petrol engine is also available for sale in the Ford Edge crossover and was announced at the NAIAS for the new 2017 Ford Fusion, where it will be the exclusive engine option for the Fusion Sport.
"As auto shows evolve to focus more on mobility and connectivity than on driving and powertrain technology, it is rewarding to have our technology recognised in a variety of vehicle applications" said Dr. Steve Dawson, President & CEO of SinterCast. "New engines and new vehicle applications provide important growth opportunities for SinterCast. If the Lincoln Continental and the Nissan Titan approach their stated sales ambitions, the incremental growth from these two vehicles alone provides the potential to add 10% to our current series production volume."
For more information:
|Dr. Steve Dawson|
|President & CEO|
|SinterCast AB (publ)|
|Tel:||+46 8 660 7750|
SinterCast is the world's leading supplier of process control technology for the reliable high volume production of Compacted Graphite Iron (CGI). With at least 75% higher tensile strength, 45% higher stiffness and approximately double the fatigue strength of conventional grey cast iron and aluminium, CGI allows engine designers to improve performance, fuel economy and durability while reducing engine size, weight, noise and emissions. The SinterCast technology, with 44 installations in 13 countries, is primarily used for the production of petrol and diesel engine cylinder blocks and exhaust components for passenger vehicles, medium-duty and heavy-duty cylinder blocks and heads for commercial vehicles, and industrial power engine components for marine, rail, off-road and stationary engine applications. SinterCast's series production components range from 2 kg to 9 tonnes, all using the same proven process control technology. The SinterCast share is quoted on the Small Cap segment of the Stockholm NASDAQ OMX stock exchange (Stockholmsbörsen: SINT). For more information: http://www.sintercast.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: SinterCast via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
Nasdaq Welcomes I-AM Capital Acquisition Company (Nasdaq: IAMXU) to The Nasdaq Stock Market17.8.2017 18:50 | Pressmeddelande
NEW YORK, Aug. 17, 2017 (GLOBE NEWSWIRE) -- I-AM Capital Acquisition Company (Nasdaq:IAMXU), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, celebrated its initial public offering (IPO) on The Nasdaq Stock Market. I-AM Capital's founders, Chief Executive Officer F. Jacob Cherian and Chief Financial Officer Suhel Kanuga, have been focused on investing into India over the last decade, with the distinction of completing the first listed-SPAC investment in India. "Through our keen focus and unique accomplishments in India over the last decade, we have seen our investment thesis bear fruit: India's prominence and rise on the world stage, its distinction as being one of the fastest growing major economies of the world, and its strong vibrant consumer demographics. We believe these factors are aligning well now,
Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency17.8.2017 14:30 | Pressmeddelande
WATERTOWN, Mass., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant (MDR) infections, today announced that the Marketing Authorization Application (MAA) for IV eravacycline for the treatment of complicated intra-abdominal infections (cIAI) has been submitted and was validated by the European Medicines Agency (EMA). Eravacycline is a novel, fully-synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. The MAA filing is based on data from the phase 3 IGNITE1 clinical trial in which eravacycline was well tolerated and demonstrated statistical non-inferiority to ertapenem using the primary endpoint of clinical response at the test-of-cure (TOC) visit. "The MAA filing represents a significant milestone for Tetraphase as it is our
RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules17.8.2017 13:00 | Pressmeddelande
RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories Esomeprazole Strontium DR Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI), indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions RedHill expects to initiate the U.S. promotion of Esomeprazole Strontium DR Capsules 49.3 mg in the coming weeks Esomeprazole Strontium DR Capsules 49.3 mg will be the third commercial GI product to be promoted by RedHill in the U.S. RedHill's GI-focused sales force currently promotes two GI s
Brand Industrial Services Announces Agreement to Acquire Venko Groep BV16.8.2017 19:40 | Pressmeddelande
Complementary core strengths provide broader range of services for customers KENNESAW, GA, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has signed an agreement to acquire Venko Groep BV, a portfolio company of Mentha Capital. Venko will become a part of the Brand Energy & Infrastructure Services (Brand) group. "We are very pleased to announce the agreement with Venko," said Bill Hayes, President and CEO of BrandSafway. "Our combined customers in Europe will benefit from a broader range of solutions and greater depth of expertise in access, insulation and coatings. Bringing Venko's highly specialized knowledge in coatings to BrandSafway will provide the expertise we need to expand our services in the offshore market worldwide." Based in the Netherlands, with a focus on operations in the North Sea area, Venko is a leading offshore and onshore coatings maintenance provid
Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A16.8.2017 15:38 | Pressmeddelande
NEW YORK and CLEVELAND, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced the pivotal expansion of its gene therapy clinical trials for patients with MPS IIIA in the USA, Europe and Australia. "We have completed the necessary regulatory and ethical committee approvals and site initiations in Europe and Australia in order to accelerate enrollment," stated Juan Ruiz, M.D., Ph.D., Abeona's Chief Medical Officer. "We remain very encouraged by the improvements observed in clinically relevant biomarkers post-dosing of ABO-102, including durable reductions in heparan sulfate measured in the CNS, reduction of organ disease pathology, and signals of CNS improvement or stabilization at one-year follow-up in Cohort 1 subjects, and look forward to providing a more fulsome clinical update at important clinical
CallidusCloud Wins Eight Gold Stevies® in the 2017 International Business Awards16.8.2017 14:00 | Pressmeddelande
CallidusCloud Lead to Money suite recognized as Best B2B New Product of the Year. LeadRocket voted Best New Product or Service of the Year in the Software - Lead Generation Solution category. DUBLIN, Calif., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Callidus Software Inc. (NASDAQ:CALD), a global leader in cloud-based sales, marketing, learning, and customer experience solutions, announced today that it was named the winner of eight Gold Stevie® awards in the 2017 International Business Awards. "The eight Stevie® awards earned highlight CallidusCloud's momentum, commitment to excellence, passion for innovation and customer orientation," said Leslie Stretch, president and CEO of CallidusCloud. "They also recognize the benefits that the Lead to Money suite, honored as the Best New Product in Business-to-Business, accrues to its customers in terms of enabling faster, bigger, and more profitable sales." CallidusCloud's Go
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum